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Wuotations From
nticipated Coronary
eart Disease Mortality Trends
n a recent editorial published in the Journal, Greenland and Lloyd-
ones (1) commented on coronary heart disease mortality trends in the
.S. (2). They quoted an editorial by Brown and Goldstein (3) by
tating that these authors were “proclaiming the ‘end of heart attacks
y the century.’ ” The original editorial by Brown and Goldstein (3)
recisely stated that “recent breakthroughs . . . may well end coronary
isease as a major public health problem early in the next century.”
rown and Goldstein were also said to predict “that current knowl-
dge, if fully applied, could end heart attacks within a short time” (1).
rown and Goldstein (3) did not proclaim the end of heart attacks
nd used vague language (“may”) to stress the speculative nature of
heir beliefs. The eye-catching title of Brown and Goldstein’s editorial
Heart Attacks: Gone With the Century?” (3) is formulated as a
uestion only. Furthermore, if the incidence, mortality, adverse
uality of life, and high costs of coronary heart disease were markedly
iminished and no longer a major public health problem, this would
ot necessarily imply that heart attacks would no longer occur.
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enomics of Aortic Valve Disease
read with great interest the recent article by Bossé et al. (1) that
ummarized the molecular mechanisms underlying calcific aortic
alve disease, the genetic epidemiology of calcific aortic valve
isease, and advances in genomic approaches and their applications oo elucidating calcific aortic valve disease. Indeed, recent studies
ave indicated that calcific aortic valve disease is influenced by
enetic factors, and the article provided a succinct review of the
iterature. However, the authors may have “overstated” their
ssertion that there are no other heritability or inheritance studies
hat have reported on calcific aortic valve disease other than those
eporting on the bicuspid aortic valve. Using an affected sibpair
esign, we performed genome-wide linkage analysis in African-
merican and white hypertensive sibships participating in the
ypertension Genetic Epidemiology Network Study and found
trong evidence of linkage of aortic valve sclerosis to chromosome
6q22.1–q22.3 (logarithm of odds [LOD] score 3.1) (2). There
as also suggestive evidence of linkage of aortic valve sclerosis to
hromosome 19p13.11–p11 (LOD score 2.88), another position
n chromosome 16q22.1–q22.3 (LOD score 2.63), chromosome
q42 (LOD score  2.12), and chromosome 2q37 (LOD score 
.03). The presence of multiple peaks in several chromosomal
egions suggests pleiotropy in susceptibility genes predisposing to
ortic valve sclerosis. The study extended the report from Probst et
l. (3) that showed clusters of families affected by aortic valve
tenosis and that also indicated that offspring of affected individ-
als had aortic valve sclerosis, suggesting that aortic valve sclerosis
ay be an early manifestation of familial aortic valve stenosis.
urther studies are underway to identify the specific genes con-
ained in these novel chromosomal regions we found in the study
hat are responsible for the observed linkage results. Although the
dentification of genes influencing calcific aortic valve disease is
hallenging, it offers much promise in defining novel mechanistic
aradigms and developing therapeutic strategies in the prevention
nd treatment of calcific aortic valve disease.
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eply
e appreciate the precision comments by Dr. Bella concerning
ur recent review on the genetics/genomics of calcific aortic valve
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499JACC Vol. 52, No. 6, 2008 Correspondence
August 5, 2008:498–500tenosis (1). The Hypertension Genetic Epidemiology Network
HyperGEN) Study Group conducted a genome-wide linkage
can on aortic valve sclerosis (2) that deserves to be discussed. This
yperGEN cohort was a substudy of a larger National Heart,
ung, and Blood Institute program, the Family Blood Pressure
rogram, designed to search for hypertension/blood pressure
enes. The authors reported familial aggregation of aortic valve
clerosis with a sibling recurrence risk ratio of 2.3 and identified
any linkage signals throughout the genome, suggesting the
ultilocus nature of aortic valve sclerosis. However, their results
lso highlighted the challenge of collecting samples of a sufficient
ize to study this disease. Major research resources were invested in
he HyperGEN cohort to phenotype and genotype 1,871 patients.
owever, in the end, only 41 patients with isolated aortic valve
clerosis from families with at least 2 affected siblings were
nformative for the genetic linkage analyses. The authors also
ecognized the limitation of their ascertainment scheme that was
ased on hypertension to identify genetic loci influencing aortic
alve sclerosis. Accordingly, recycling data from larger studies
onducted on related traits provided a cost-effective way to identify
ew leads. However, studies specifically designed to study calcific
ortic valve disease are likely to be more powerful and are clearly
arranted.
By addressing study design and focusing on genomic approaches
hat are likely to be more successful, we should re-emphasize the
eed for genome-wide association scans on case-control studies.
he identification of genes of complex diseases by this approach
as considered one of the scientific breakthroughs of the year in
007 (3). In contrast, genome-wide linkage studies have been used
xtensively in the past and have proven to be very productive to
dentify genes for monogenic traits. However, limited success has
een reported for complex diseases (4), and a good example is the
esults from the Family Blood Pressure Program (5). Even in
tudies in which strong linkage peaks were originally identified,
ositional cloning attempts to find the causal genes responsible for
he linkage signals have often been disappointing (4). Hence, the
rticle by Bella et al. (2) is certainly worth mentioning, but the
esults of this study also provide an impetus for the design and
ealization of future genomic studies with a population and
ethodology that are more suitable for a complex disease such as
alcific aortic valve stenosis.
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laque Rupture: Plaque Stress,
hear Stress, and Pressure Drop
e read with interest the article by Fukumoto et al. (1) in a
revious issue of the Journal. They used 3-dimensional intravas-
ular ultrasound and computational fluid dynamics (CFD) to study
all shear stress (WSS) distribution in arteries with ruptured
laques. Their results showed that there are local elevations of
SS concentrations at proximal sites in the plaques and that these
orrespond to the rupture sites.
We want to emphasize that WSS is calculated as blood viscosity
ultiplied by the derivative of flow velocity with respect to the
istance from the vessel wall (    u/y). Flow velocity varies
long the stenotic artery across the plaque as the lumen narrows.
enerally the maximum WSS should be at the location of the
aximum stenosis, where the velocity is the highest and the lumen
iameter is the smallest. There should not be any local elevation of
SS concentration if the lumen surface is smooth and there are no
ad mesh elements. The use of image-based CFD can often cause
roblems with the geometry reconstruction and mesh generation.
SS is largely dependent on the geometry. Therefore, any effort
o improve the model reconstruction and mesh generation is useful
o improve the accuracy of the WSS calculation.
Pressure distribution across the stenosis is not shown in the
rticle (1); it is not clear how pressure boundary condition was
iven in this study, but it is thought to be more important for
laque vulnerability. There is a pressure drop across the plaque
ecause of the stenosis. According to the Bernoulli principle, this
ncreased blood velocity produces a lower lateral blood pressure
cting on the plaque. Thus, a pressure gradient build-up is created
cross the plaque that could rupture it. Any increase in systemic
ressure or increase in the narrowing of the lumen would further
ncrease the velocity through the narrowed lumen and increase the
ressure drop. Furthermore, the magnitude of the pressure drop is
uch higher than the WSS. It can be tens to hundreds of times the
agnitude of WSS for different degrees of stenosis.
Plaque stress (stress within the plaque) may be a more important
actor when the mechanism of plaque rupture is considered. The
rterial wall continuously interacts with hemodynamic forces,
hich include WSS and blood pressure. Plaque stress is the result
f external hemodynamic forces. Plaque rupture itself represents
tructural failure of a component of the diseased vessel, and it is
herefore reasonable to propose that the biomechanical properties
f atheromatous lesions may influence their vulnerability to rup-
ure. Recognizing which features contribute to this increased
ulnerability may improve risk stratification and allow aggressive
nterventions to be targeted at patients with plaques that are prone
